University College London at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University College London takes part in 2 sessions at ASH 2026 in New Orleans. Its program pairs leukemia treatment with basic blood biology. It covers how to order therapies in ALL, from asparaginase to cell therapy guided by residual disease, and how blood formation is organised in space and time.
| Organization | ASH 2026 Attendance |
|---|---|
University College London London, United Kingdom | |
Public research university in London with large medical and life-sciences faculties. | Symposium Fri Dec 11 3:00pm–6:00pm Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing. Session Through Space and Time: Spatiotemporal Organization of Haematopoiesis in Health and Disease Blood stem cells do not share one uniform niche, and location, chromosome dosage, and body-wide feedback shape them in development, disease, and aging. |
Instantly find 20 buyers from University College London
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction